These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15513412)

  • 1. Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
    Beilke MA
    Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
    DeSimone JA; Ojha A; Pathak R; Cohn J
    Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 4. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 7. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide.
    Quiros-Roldan E; Tirelli V; Torti C; Sosta E; Tosoni C; Damiolini E; Carosi G
    AIDS; 2007 Jun; 21(10):1388-9. PubMed ID: 17545726
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Polizzotto MN; Street AM; Wright E
    Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
    Tashima KT; Carpenter CC
    N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.
    Shahar E; Moar C; Pollack S
    AIDS; 2005 Mar; 19(4):451-2. PubMed ID: 15750403
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.
    AIDS Alert; 2003 Jun; 18(6):78-9. PubMed ID: 12866478
    [No Abstract]   [Full Text] [Related]  

  • 14. Enfurvirtide safety in human immunodeficiency virus-infected children.
    Baylor MS; Johann-Liang R
    Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
    [No Abstract]   [Full Text] [Related]  

  • 15. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 16. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV infection--a new drug and new costs.
    Steinbrook R
    N Engl J Med; 2003 May; 348(22):2171-2. PubMed ID: 12773643
    [No Abstract]   [Full Text] [Related]  

  • 18. [Enfuvirtide desensitisation: due to a failed case].
    López-de-Torre Querejazu A; Ibarra Barrueta O; Santos Ibañez A; Mayo Suárez J
    Farm Hosp; 2012; 36(2):112-3. PubMed ID: 22024011
    [No Abstract]   [Full Text] [Related]  

  • 19. New partnership calls for clinical testing of two fusion inhibitors.
    Slovick J
    Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
    [No Abstract]   [Full Text] [Related]  

  • 20. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.